{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T18:50:47Z","timestamp":1781981447878,"version":"3.54.5"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22077018"],"award-info":[{"award-number":["22077018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2017YFA0506000"],"award-info":[{"award-number":["2017YFA0506000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejmech.2022.114939","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T11:00:38Z","timestamp":1669287638000},"page":"114939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs"],"prefix":"10.1016","volume":"246","author":[{"given":"Ruo-Lan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiran","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Pannecouque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik De","family":"Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0718-1820","authenticated-orcid":false,"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen-Er","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114939_bib1","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.2174\/138161212802430440","article-title":"The development of HEPT-type HIV non-nucleoside reverse transcriptase inhibitors and its implications for DABO family","volume":"18","author":"Chen","year":"2012","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2022.114939_bib2","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1021\/acs.jmedchem.1c01758","article-title":"Contemporary medicinal chemistry strategies for the discovery and development of novel HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114939_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114512","article-title":"Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase","volume":"238","author":"Ling","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114939_bib4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nm0703-867","article-title":"Twenty years of therapy for HIV-1 infection","volume":"9","author":"Pomerantz","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114939_bib5","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/med.21760","article-title":"Druggability modification strategies of the diarylpyrimidine-type non-nucleoside reverse transcriptase inhibitors","volume":"41","author":"Ding","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2022.114939_bib6","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.apsb.2019.11.010","article-title":"Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years","volume":"10","author":"Zhuang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2022.114939_bib7","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1021\/acs.biochem.6b00113","article-title":"Conformational plasticity of the NNRTI-binding pocket in HIV-1 reverse transcriptase: a fluorine nuclear magnetic resonance study","volume":"55","author":"Sharaf","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114939_bib8","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.2174\/092986711795843209","article-title":"Recent advances in the DABOs family as potent HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"18","author":"Yu","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114939_bib9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejmech.2006.09.018","article-title":"Synthesis and anti-HIV activity evaluation of 1-[(alkenyl or alkynyl or alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors","volume":"42","author":"Ji","year":"2007","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114939_bib10","doi-asserted-by":"crossref","first-page":"8712","DOI":"10.1021\/acs.jmedchem.6b00472","article-title":"The \"cyclopropyl fragment\" is a versatile player that frequently appears in preclinical\/clinical drug molecules","volume":"59","author":"Talele","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114939_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111874","article-title":"Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors","volume":"185","author":"Han","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114939_bib12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/anie.201610797","article-title":"Chemoselective suzuki-miyaura cross-coupling via kinetic transmetallation","volume":"56","author":"Fyfe","year":"2017","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2022.114939_bib13","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1248\/cpb.53.886","article-title":"Nonnucleoside HIV-1 reverse-transcriptase inhibitors, part 5. Synthesis and anti-HIV-1 activity of novel 6-naphthylthio HEPT analogues","volume":"53","author":"Sun","year":"2005","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ejmech.2022.114939_bib14","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ejmech.2014.05.059","article-title":"Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors","volume":"82","author":"Meng","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114939_bib15","doi-asserted-by":"crossref","first-page":"11430","DOI":"10.1021\/acs.jmedchem.9b01446","article-title":"Ligand-based design of nondimethylphenyl-diarylpyrimidines with improved metabolic stability, safety, and oral pharmacokinetic profiles","volume":"62","author":"Sang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114939_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112290","article-title":"hERG toxicity assessment: useful guidelines for drug design","volume":"195","author":"Garrido","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114939_bib17","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1021\/acs.jmedchem.9b01769","article-title":"Discovery and characterization of fluorine-substituted diarylpyrimidine derivatives as novel HIV-1 NNRTIs with highly improved resistance profiles and low activity for the hERG ion channel","volume":"63","author":"Kang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114939_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/13543776.2017.1303046","article-title":"Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1","volume":"27","author":"Kang","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2022.114939_bib19","doi-asserted-by":"crossref","first-page":"10297","DOI":"10.1021\/acs.jmedchem.1c00708","article-title":"Improving druggability of novel diarylpyrimidine NNRTIs by a fragment-based replacement strategy: from biphenyl-DAPYs to heteroaromatic-biphenyl-DAPYs","volume":"64","author":"Ding","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114939_bib20","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1074\/jbc.TM118.004144","article-title":"Cytochrome P450 research and the journal of biological chemistry","volume":"294","author":"Guengerich","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114939_bib21","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1021\/acs.jmedchem.0c00117","article-title":"Structure-based bioisosterism yields HIV-1 NNRTIs with improved drug-resistance profiles and favorable pharmacokinetic properties","volume":"63","author":"Kang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114939_bib22","first-page":"228","article-title":"Synergistic Pd\/Cu catalysis for stereoselective allylation of vinylethylene carbonates with glycine iminoesters: enantioselective access to diverse trisubstituted allylic amino acid derivatives","volume":"2","author":"Ke","year":"2021","journal-title":"Green Synth. Catal."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422008418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422008418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:44:12Z","timestamp":1759329852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422008418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":22,"alternative-id":["S0223523422008418"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114939","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-guided design of novel HEPT analogs with enhanced potency and safety: From Isopropyl-HEPTs to Cyclopropyl-HEPTs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114939","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114939"}}